Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TIGER-2: A Phase 2, Open-Label, Multicenter, Safety and Efficacy Study of Oral CO-1686 as 2nd Line EGFR-Directed TKI in Patients With Mutant EGFR Non-Small Cell Lung Cancer (NSCLC) With the T790M Resistance Mutation

Trial Profile

TIGER-2: A Phase 2, Open-Label, Multicenter, Safety and Efficacy Study of Oral CO-1686 as 2nd Line EGFR-Directed TKI in Patients With Mutant EGFR Non-Small Cell Lung Cancer (NSCLC) With the T790M Resistance Mutation

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2018

At a glance

  • Drugs Rociletinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms TIGER-2
  • Sponsors Clovis Oncology
  • Most Recent Events

    • 07 Sep 2018 Planned primary completion date changed from 1 Dec 2016 to 31 Aug 2019.
    • 07 Sep 2018 Status changed from discontinued to active, no longer recruiting.
    • 16 Mar 2017 This trial has been completed in Spain as per European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top